Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 8/20 | 0.69 |
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 7/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940117 | 1.00 | MMEL1 (0.69) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15947115 | 0.94 | MMEL1 (0.61) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15947116 | 0.94 | MMEL1 (0.61) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15947120 | 0.93 | MMEL1 (0.60) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15948921 | 0.91 | MMEL1 (0.57) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15947127 | 0.90 | MMEL1 (0.57) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15940111 | 0.84 | MMEL1 (0.60) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15940304 | 0.84 | MMEL1 (0.60) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15940159 | 0.82 | MMEL1 (0.52) | MMEL1MMEITGB1ITGA4CTSA | |
| SCHEMBL15940160 | 0.82 | MMEL1 (0.52) | MMEL1MMEITGB1ITGA4CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956445-A1 | SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY | Novartis AG (CH) | 2015-12-23 | — | — | EP | disclosed |
| US-9102635-B2 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2014126972-A1 | SUBSTITUTED BISPHENYL BUTANOIC ACID DERIVATIVES AS NEP INHIBITORS WITH IMPROVED IN VIVO EFFICACY | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228415-A1 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228415-A1 | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy | MME, REN, ACE | MMEL1 424/4885MME 1/4885ITGB1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.